吃瓜不打烊

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Healthcare Helpline
    • 吃瓜不打烊 Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • Common Ground
    • Diagnosis: Debt
    • The Body Shops
    • Priced Out
    • Guns, Race, and Profit
    • Broken Rehab
    • Dead Zone
    • Denied
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Healthcare Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health
    All Topics

  • Medicare Advantage Billing Probe
  • School Vaccine Mandates
  • Weight Loss Drugs Coverage
  • Opioid Settlement Money
  • Abortion Pill Access

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Monday, Jan 30 2017

Full Issue

After Aetna's Courtroom Defeat On Antitrust Issues, Era Of Mega-Mergers May Be Reaching Its End

In other health news from the insurance marketplace, Anthem's earnings report could rise by as much as 30 percent.

The consolidation among the biggest health insurance players that seemed so inevitable not long ago may fizzle into a series of smaller deals aimed at growing market share in Medicare and Medicaid plans. Aetna's $37 billion play for Humana, announced 19 months ago, appeared to be on its deathbed last week. A federal judge issued an order blocking the transaction, agreeing with the U.S. Justice Department's arguments that allowing it to happen would harm consumers in the Medicare Advantage and individual insurance markets. (Livingston, 1/28)

Anthem Inc shares could rise by 30 percent as the U.S. health insurer is undervalued and has the most room for improvement in profit margins and earnings among its peers, Barron's reported. The company also has the lowest price-to-earnings ratio among its peers including UnitedHealth Group Inc and Aetna, Barron's said, adding that the stock trades at just 13 times the projected 2017 earnings, a discount to its four big rivals. (Kumar, 1/29)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, August 3
  • Friday, July 31
  • Thursday, July 30
  • Wednesday, July 29
  • Tuesday, July 28
  • Monday, July 27
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • 吃瓜不打烊
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

漏 2026 KFF